Cystic Fibrosis Carrier Screening & Diagnostic

This test is a genetic screen to identify if you are a carrier of cystic fibrosis and is available to order and pay online.

You must have a completed doctors request form to order this test.


The cost of this test is AUD$212.50.

Medicare eligibility

Patients may be eligible for a Medicare rebate, if:

  • they present with symptoms of cystic fibrosis or CFTR* related disorder
  • they have a close family history of cystic fibrosis (first cousin once removed, or closer)
  • their reproductive partner has cystic fibrosis, or is a carrier of cystic fibrosis
  • their fetus shows ultrasonic evidence of echogenic gut.

For more information about eligibility or item numbers, please refer to the Medicare Benefits Schedule website or contact us to discuss.

Did you know that cystic fibrosis carrier screening can be performed using saliva collection?

Saliva testing is:

  • simple and painless
  • suitable for any age group
  • robust stable for two months once taken
  • exceptional quality.

Genetic counselling available

For more information about cystic fibrosis or to make an appointment with a genetic counsellor, email [email protected] or phone (03) 9936 6402.

Cystic Fibrosis Community Care

VCGS work in partnership with Cystic Fibrosis Community Care (CFCC) to raise awareness and improve access to genetic carrier screening. This collaboration ensures individuals and families considering or undergoing screening have access to high quality information and support Find our more at cfcc.org.au

View test and specification requirements

* cystic fibrosis transmembrane conductance regulator (CFTR)

Single Gene Diagnostics

Angelman syndrome (AS) is characterised by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and a unique behaviour with an overly happy demeanour that includes frequent laughing, smiling, and excitability. Developmental delays are first noted at around age six months; however, the clinical features of AS do not become apparent until after age one year. Angelman syndrome has multiple causes, all affecting chromosome region 15q11.1-q11.3.

View Test & Specification requirements

Charcot-Marie-Tooth neuropathy type 1 (CMT1) is a demyelinating peripheral neuropathy characterised by distal muscle weakness and atrophy and sensory loss. It is usually slowly progressive and often associated with pes cavus foot deformity and bilateral foot drop. Affected individuals usually become symptomatic between age five and 25 years.

View Test & Specification requirements

Cystic fibrosis (CF) is an inherited condition affecting breathing and digestion. CF causes the build-up of thick mucus which traps bacteria, resulting in recurrent infections that damage the lungs. Thick mucus in the gut also makes digestion of food difficult. People with CF require daily physiotherapy to clear mucus from their lungs, frequent courses of antibiotics and need to take medicine to help with digestion. There is no cure for CF but better treatments are under research and development.

View Test & Specification requirements

Dentatorubral-pallidoluysian atrophy (DRPLA) is a progressive disorder of ataxia, myoclonus, epilepsy, and progressive intellectual deterioration in children and ataxia, choreoathetosis, and dementia or character changes in adults. Age of onset varies from childhood through to late adulthood.

View Test & Specification requirements

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are types of neuromuscular disorders that affect the nerves and the muscles. Whilst both involve the DMD gene, Becker muscular dystrophy has a milder presentation.

View Test & Specification requirements

Fragile X syndrome (FXS) is the most common cause of inherited intellectual disability. People with FXS can have developmental delay, learning difficulties, anxiety, autism and epilepsy. The features of FXS vary from mild to severe with males more likely to be severely affected than females because the gene is found on the X-chromosome.

View Test & Specification requirements

Friedreich ataxia (FRDA) is characterised by slowly progressive ataxia which becomes apparent between age ten and 15 years. FRDA is typically associated with muscle weakness which impacts on speech, heart function, spasticity in the lower limbs and scoliosis, approximately one third of individuals with FRDA will also develop diabetes mellitus.

View Test & Specification requirements

Nonsyndromic hearing loss is a partial or total loss of hearing that is not associated with other signs and symptoms. Nonsyndromic hearing loss can be caused by alterations in over 90 genes however the most commonly associated genes are GJB2 and GJB6 genes. The GJB2 and GJB6 genes provides instructions for making the connexin 26 and connexin 30 proteins respectively. Alterations in the GJB2 or GJB6 gene change their connexin proteins, which may affect the function or survival of cells that are needed for hearing. VCGS offers diagnostic, prenatal and carrier testing.

View Test & Specification requirements

Huntington disease is a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability (cognition).

View Test & Specification requirements

This MLPA assay for analysis of the OTOA, STRC, CATSPER2 genes accounts for the majority of SNHL associated copy number changes and is suitable as a second tier test following a negative result from GJB2/GJB6 (Connexin 26/30) testing.

View Test & Specification requirements

Myotonic dystrophy type 1 (DM1) is a multisystem disorder that affects skeletal and smooth muscle as well as the eye, heart, endocrine system and central nervous system. Myotonic dystrophy has three categories: mild, classic, and congenital. Congenital DM1 is the severist form of DM1 and is characterised by hypotonia and severe generalised weakness at birth, often with respiratory insufficiency; intellectual disability is common. DM1 is caused by the alteration of the DMPK gene.

View Test & Specification requirements

Prader-Willi syndrome (PWS) is characterised by severe hypotonia and feeding difficulties in early infancy, followed in later infancy or early childhood by excessive eating and gradual development of morbid obesity (unless eating is externally controlled). All individuals have some degree of cognitive impairment. Prader-willi has multiple causes, all affecting chromosome region 15q11.1-q11.3.

View Test & Specification requirements

SMA is an autosomal recessive condition that affects nerves in the spinal cord and causes muscles to get progressively weaker. There are four types of SMA with SMA type 1 being the most common and most severe. Babies with SMA type 1 have weak muscles from birth and usually do not live past two years of age. SMA types 2 and 3 are less severe than type 1 and symptoms typically develop in childhood. SMA type 4 is the mildest form and develops during adulthood. There is no cure for SMA, however treatment is aimed at managing symptoms and improving quality of life.

View Test & Specification requirements

Spinocerebellar ataxia (SCA) is a progressive, degenerative, genetic disease with multiple types, each of which could be considered a disease in its own right.

View Test & Specification requirements

We all have 23 pairs of chromosomes with one chromosome of each pair coming from each parent. Uni-parental disomy (UPD) occurs when both copies of the one chromosome come from one parent. For most chromosomes this does not affect how we develop, but a for a small group of chromosomes this can result in a group of unrelated conditions called imprinting disorders. UPD of chromosomes 6,7,11,14 and 15 are known to be associated with genetic conditions.

View Test & Specification requirements